Early intravenous unfractionated heparin and outcome in acute lung injury and acute respiratory distress syndrome: a retrospective propensity matched cohort study
- PMID: 22894723
- PMCID: PMC3517343
- DOI: 10.1186/1471-2466-12-43
Early intravenous unfractionated heparin and outcome in acute lung injury and acute respiratory distress syndrome: a retrospective propensity matched cohort study
Abstract
Background: Acute lung injury (ALI) is characterized by a pro-coagulant state. Heparin is an anticoagulant with anti-inflammatory properties. Unfractionated heparin has been found to be protective in experimental models of ALI. We hypothesized that an intravenous therapeutic dose of unfractionated heparin would favorably influence outcome of critically ill patients diagnosed with ALI.
Methods: Patients admitted to the Intensive Care Unit (ICU) of a tertiary referral center in the Netherlands between November 2004 and October 2007 were screened. Patients who developed ALI (consensus definition) were included. In this cohort, the impact of heparin use on mortality was assessed by logistic regression analysis in a propensity matched case-control design.
Results: Of 5,561 admitted patients, 2,138 patients had a length of stay > 48 hours, of whom 723 were diagnosed with ALI (34%), of whom 164 received intravenous heparin. In a propensity score adjusted logistic regression analysis, heparin use did not influence 28-day mortality (odds ratio 1.23 [confidence interval 95% 0.80-1.89], nor did it affect ICU length of stay.
Conclusions: Administration of therapeutic doses of intravenous unfractionated heparin was not associated with reduced mortality in critically ill patients diagnosed with ALI. Heparin treatment did not increase transfusion requirements. These results may help in the design of prospective trials evaluating the use of heparin as adjunctive treatment for ALI.
Figures


Similar articles
-
Early intravenous unfractionated heparin and mortality in septic shock.Crit Care Med. 2008 Nov;36(11):2973-9. doi: 10.1097/CCM.0b013e31818b8c6b. Crit Care Med. 2008. PMID: 18824906
-
Epidemiological features and risk factor analysis of children with acute lung injury.World J Pediatr. 2012 Feb;8(1):43-6. doi: 10.1007/s12519-012-0334-8. Epub 2012 Jan 27. World J Pediatr. 2012. PMID: 22282381
-
Risk factors for physical impairment after acute lung injury in a national, multicenter study.Am J Respir Crit Care Med. 2014 May 15;189(10):1214-24. doi: 10.1164/rccm.201401-0158OC. Am J Respir Crit Care Med. 2014. PMID: 24716641 Free PMC article. Clinical Trial.
-
Monitoring of unfractionated heparin in critically ill patients.Neth J Med. 2013 Nov;71(9):466-71. Neth J Med. 2013. PMID: 24218420 Review.
-
[Statin in the treatment of ALI/ARDS: a systematic review and Meta-analysis based on international databases].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017 Jan;29(1):51-56. doi: 10.3760/cma.j.issn.2095-4352.2017.01.011. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28459404 Chinese.
Cited by
-
Heparin-binding protein is important for vascular leak in sepsis.Intensive Care Med Exp. 2016 Dec;4(1):33. doi: 10.1186/s40635-016-0104-3. Epub 2016 Oct 4. Intensive Care Med Exp. 2016. PMID: 27704481 Free PMC article.
-
Exploring the therapeutic role of early heparin administration in ARDS management: a MIMIC-IV database analysis.J Intensive Care. 2024 Feb 26;12(1):9. doi: 10.1186/s40560-024-00723-5. J Intensive Care. 2024. PMID: 38409068 Free PMC article.
-
Postexposure aerosolized heparin reduces lung injury in chlorine-exposed mice.Am J Physiol Lung Cell Mol Physiol. 2014 Sep 1;307(5):L347-54. doi: 10.1152/ajplung.00152.2014. Epub 2014 Jul 18. Am J Physiol Lung Cell Mol Physiol. 2014. PMID: 25038191 Free PMC article.
-
Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis.Vascul Pharmacol. 2021 Aug;139:106882. doi: 10.1016/j.vph.2021.106882. Epub 2021 Jun 2. Vascul Pharmacol. 2021. PMID: 34087481 Free PMC article.
-
Roles of oral anticoagulant use on the risk of 28-day mortality and in-hospital mortality in patients with acute respiratory distress syndrome.Front Pharmacol. 2025 May 14;16:1565312. doi: 10.3389/fphar.2025.1565312. eCollection 2025. Front Pharmacol. 2025. PMID: 40438607 Free PMC article.
References
-
- Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia–a review. Crit Care Med. 2006;34:871–877. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical